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Abstract 
A systematic review and meta-analysis was performed to determine the relationship between 
testosterone therapy and risk of recurrence in testosterone-deficient survivors of curatively 
treated high-risk prostate cancer. Primary outcome was the risk of biochemical recurrence 
(BCR) in 109 high-risk patients in 13 included studies (1997-2017). Biochemical and 
symptomatic effects of therapy were also reviewed. The BCR rate was 0.00 (0.00-0.05), 
lower than the expected rate for high-risk prostate cancer survivors, suggesting that 
testosterone therapy may not increase their BCR risk. However, this is uncertain as the 
available evidence is of very low quality. Testosterone therapy remains investigational in this 
group.  
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Introduction 
Testosterone deficiency is increasingly diagnosed in survivors of prostate cancer (1, 2). It can 
severely impact quality of life as well as physical and mental health: effects include reduced 
libido, osteoporosis and cognitive impairment (1, 3-5). It has also been implicated in various 
comorbidities, such as diabetes and obesity (6), and correlates with reduced life expectancy. 
Although the relationship between testosterone therapy and cardiovascular health is 
controversial (7), testosterone therapy has wide-ranging benefits for those suffering from 
deficiency (8). Despite this, testosterone-deficient patients with a history of prostate cancer, 
especially high-risk prostate cancer, are not routinely treated (1, 2, 9-13).  
 
The origins of concerns and controversy about the relationship between testosterone and 
prostate cancer date back to a landmark study by Huggins and Hodges in 1941. (9) They 
found that in both healthy controls and in men with prostatic malignancy, injecting androgens 
increased their serum phosphatase levels, indicating increased neoplastic activity. 
Conversely, both castration and oestrogenic injections reduced their serum phosphatase 
levels. The conclusion was that prostate cancer progression could be worsened by increasing 
androgen levels and slowed by castration or administration of oestrogen. A further study by 
Huggins and Hodges demonstrated clinical improvement in patients with advanced prostatic 
malignancy following castration, as well as exacerbation of symptoms with administration of 
exogenous testosterone. (14) This work would go on to earn Huggins the 1966 Nobel Prize in 
Physiology and Medicine. It was echoed by subsequent studies documenting negative 
outcomes of administering exogenous testosterone to patients with advanced or metastatic 
prostate cancer. (11, 12) Thus the androgen-dependency theory, the rationale for the use of 
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 4 
androgen-deprivation therapy (ADT) to treat prostate cancer, was formed: the more 
testosterone the greater the prostate cancer risk. (2) 
 
Despite the enduring impact of the androgen-dependency theory on clinical practice, it is 
contradicted by recent findings that neither high endogenous nor exogenous testosterone 
levels increase the risk of de novo or recurrent prostate cancer (15, 16). Contrary to 
expectations, low testosterone levels have been found to correlate with development of more 
aggressive prostate cancer (2, 17), while low recurrence rates have been reported in patients 
receiving testosterone while they have active prostate cancer (18-22). Research has even 
begun into the therapeutic potential of high dose testosterone and ‘bipolar androgen therapy’ 
to treat prostate cancer (23, 24). New theories have emerged, including the prostate saturation 
model proposed by Morgentaler et al (6), whereby prostate cells are vulnerable to changes in 
testosterone level at low levels, but prostatic androgen receptors become saturated at 250 
ng/ml of serum testosterone, beyond which increases in testosterone no longer affect prostate 
growth or neoplastic activity (1, 6, 10, 25).  
 
To date, no systematic reviews have been published on testosterone therapy in survivors of 
specifically high-risk prostate cancer. Despite shifting attitudes, the March 2015 European 
Urological Association guidelines recommend that only patients with a history of low-risk 
prostate cancer be cautiously treated after attempts to treat comorbidities and improve 
lifestyle (5). This review aims to clarify whether survivors of curatively treated high-risk 
prostate cancer can be offered testosterone therapy to treat testosterone deficiency without 
increasing their risk of biochemical recurrence of prostate cancer. This is assessed by 
comparing the risk of biochemical recurrence (BCR) in testosterone-deficient survivors of 
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 5 
curatively treated high-risk prostate cancer receiving testosterone therapy against expected 
recurrence rates in survivors of curatively treated high-risk prostate cancer. 
 
Materials and methods 
 
Search strategy 
 
This review followed PRISMA guidelines. The review was registered on PROSPERO on 
18/01/2017 under the registration number CRD42017055501. A literature search was 
performed in MEDLINE via Pubmed, Embase via Ovid and Web of Knowledge. Reference 
lists were consulted and grey literature was searched via Opengrey and Opendoar. Search 
terms included: Androgen/Testosterone, 
Therapy/Treatment/Supplementation/Replacement/Exogenous, Prostate Cancer.  
 
Study selection 
 
Of 72 relevant studies, 13 met criteria for inclusion (3, 10, 25-35). Primary human studies 
were included, and reviews, systematic reviews and meta-analyses were excluded. Studies 
were included if high-risk patients had undergone curative prostate cancer treatment: radical 
prostatectomy, radiotherapy, high-intensity focused ultrasound, cryotherapy or proton 
therapy. Studies in which high-risk patients had on-going prostate cancer at initiation of 
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testosterone therapy, or who had undergone only ADT or surgical castration, were excluded. 
Studies in which patients had undergone ADT in addition to curative therapy were included. 
Length of follow-up of patients is a key factor in determining the rate of BCR, as the number 
of recurrences in a group is expected to increase over time. However, due to limited available 
data on follow-up of high-risk patients, no minimum follow-up period was applied. Similarly, 
due to the small numbers of patients and studies available, no minimum number of high-risk 
patients was applied. Studies were excluded if they did not include sufficient data to stratify 
the patients by risk level. Abstracts were included where sufficient data was available. 
Authors of conference abstracts were contacted, and three abstracts were excluded due to 
cohort overlap with full publications. Five abstracts lacked the detailed patient characteristics 
necessary for risk grouping and inclusion. Figure 1 presents the PRISMA flow diagram of the 
literature search process. The last search date was 20/01/2017. 
 
Data extraction 
 
The 13 included studies were reviewed to identify study design, patient characteristics, 
treatment methods and outcomes. Data on the length of follow-up from initiation of 
testosterone therapy and the methods of administration of testosterone therapy was taken for 
all of the studies, but was not available for the high-risk group specifically. The primary 
outcome was rate of BCR. Secondary outcomes were changes to deficiency symptoms, 
changes to testosterone level, PSA changes and adverse effects of treatment during 
testosterone therapy. A quality assessment was performed using the validated IHE Quality 
Assessment Checklist for Case Series Studies (36-38). An additional assessment of level of 
evidence was performed using the Oxford Centre for Evidence-Based Medicine (OCEBM) 
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2011 Levels of Evidence (39). There are several classifications of risk level of prostate cancer 
survivors. The d’Amico criteria classify patients as high-risk if before prostate cancer 
treatment they have a Gleason score of 8 or greater, PSA of over 20 ng/ml, or clinical stage of 
T2c or greater (40). Seven of the included studies explicitly grouped their patients by risk 
(10, 25-27, 29, 31, 41). Of these studies, three followed the d’Amico criteria, two followed 
the National Comprehensive Cancer Network guidelines (high risk defined as T3a or greater, 
Gleason 8 or greater, PSA greater than 20 mg/ml) (29, 31) and two defined high risk as 
having a Gleason score greater than 8, positive surgical margins or positive lymph nodes after 
radical prostatectomy (10, 41). For these studies, the authors’ definition of high risk was 
accepted. Six of the included studies were not designed to group patients by risk level (3, 28, 
30, 33-35), but included sufficient information to ascertain patients’ risk level using the 
d’Amico criteria. 
 
Data processing 
 
Due to the lack of comparative randomised control trials, a single-arm meta-analysis was 
performed. A standard protocol could not be used because of the inclusion of studies with 
zero incidence of BCR in the data set. To include these low event rates, meta-analysis was 
performed using the Metaprop tool in Stata/MP 14.2. A random effects model with exact 
confidence intervals was used. A Freeman-Tukey double arcsine transformation was used to 
allow inclusion of studies with zero cases of BCR (42, 43). Heterogeneity was measured in 
Metaprop using Cochran’s Q test and the I2 index. A funnel plot to assess publication bias 
was created using the Metafunnel tool in Stata/MP 14.2. The Stata/MP 14.2 is a program of 
Stata Corp LLC.  
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Results 
 
Primary outcome 
 
The 13 studies identified for inclusion are described in Table 1. The studies included a total 
of 608 patients, of which 109 had a history of high-risk prostate cancer. There was variation 
in the method of administration of testosterone therapy and in the length of follow-up from its 
initiation, ranging from one to 189.3 months. Figure 2A demonstrates the primary outcome of 
this review as a forest plot: at 0.00 (confidence interval 0.00-0.05), there was no significant 
overall BCR rate in survivors of curatively treated high-risk prostate cancer. Thus the meta-
analysis indicates that testosterone therapy did not cause increased rates of recurrence in this 
group. The very low I
2
-value suggests that 0.00% of the variation in the included studies may 
have been due to statistical heterogeneity and the p-value of 0.72 indicates that the statistical 
heterogeneity in the included studies may not be significant, supporting the reliability of the 
review (Figure 2A). However, these statistical tests of heterogeneity may have been 
underpowered because of the small number of included studies and their small sample sizes 
(44). The funnel plot (Figure 2B) does not reveal any asymmetry, which would indicate 
publication bias. No further subgroup analysis could be performed due to small study sizes.  
 
Secondary outcomes 
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 9 
Overall, the included studies found small increases in PSA, increases in testosterone, 
improvements to patients’ symptoms of testosterone deficiency and few undesired side 
effects of testosterone therapy. However, these were inconsistently measured in the included 
studies. Additionally, the secondary outcomes were not grouped by patients’ risk level in the 
included studies, so unlike the primary outcome cannot be evaluated for high-risk survivors 
specifically. Nine studies identified increases and transient rises in PSA that did not meet 
authors’ recurrence criteria. All of the 10 studies that documented testosterone levels found 
them to be significantly increased, with the exception of a non-significant increase in 
Pastuszak et al’s high-risk patients (10). Symptom changes were monitored in eight studies. 
Two studies reported using the EPIC (Expanded Prostate Cancer Index Composite) 
questionnaire (29, 35), whilst others relied on subjective questioning or other methods. 
Patients in two of those eight studies were treated concurrently with phosphodiesterase-5 
inhibitors or intracavernosal triple therapy injections for erectile dysfunction, and patients in 
six of the included studies had received ADT as part of their prostate cancer management, 
which may have affected symptom improvements. That being said, all eight studies reported 
either a mean improvement in symptoms or an improvement in most patients. Only nine 
patients reported a lack of symptom improvement, five of whom discontinued therapy after a 
short follow-up of one to three months from its initiation – possibly too soon to reap the 
benefits of therapy. Out of 608 patients, of whom 109 were high-risk, there were only two 
cases of discontinuation of therapy due to other adverse effects (headaches and excessive 
testosterone). Two studies reported small increases in haemoglobin, but no cases of 
erythrocytosis (a known side effect of testosterone therapy) requiring treatment (5).  
 
Strengths of the review 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
   
 
 10 
 
To our knowledge, this review is the first meta-analysis to shed light on the benefits and risks 
of prescribing testosterone therapy to this specific population of high-risk survivors of 
prostate cancer. Risk stratification of patients is important as testosterone therapy becomes 
increasingly studied and prescribed because prostate cancer risk level is used to inform 
clinical guidelines and treatment decisions. This review demonstrates for the first time that 
the current evidence available, although of very low quality, is in favour of treating these 
patients.  
 
Comment 
 
Primary outcome and previous literature 
 
The meta-analysis identified a negligible rate of recurrence of 0.00 (0.00-0.05). In the 
absence of randomised controlled trials, this rate of recurrence can only be compared to 
published BCR rates of high-risk prostate cancer in men without testosterone deficiency or 
treatment. This, like the reference group in Pastuszak et al’s study, the only comparative 
study included in this review (10), does not account for a possible difference in outcome 
between survivors of prostate cancer with normal testosterone levels and survivors suffering 
with untreated testosterone deficiency. The literature values for BCR rates in high-risk 
prostate cancer survivors vary. Kim et al found a 16% and 48% risk of BCR at 27 and 28 
months after radical prostatectomy and radiotherapy respectively (45), while Arcangeli et al 
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found BCR rates of 13.2% for radiation therapy and 30.2% for prostatectomy-treated patients 
at three years (46). At five years, d’Amico et al. suggest a 50% risk of BCR after radical 
prostatectomy for high-risk patients (40). Thus the recurrence rate in this review is 
significantly lower than expected rates for patients of equivalent risk. This might indicate that 
testosterone therapy could be prescribed in this group of patients without increased risk of 
recurrence of disease compared to a population of high-risk prostate cancer survivors. This is 
in agreement with Pastuszak et al’s finding that their reference group of high-risk non-
hypogonadal men had a higher recurrence rate than their high-risk testosterone treatment 
group (10).  
 
Secondary outcomes and previous literature 
 
The secondary outcomes of the review, although they could not be assessed for high-risk 
patients specifically due to limited data in the included studies, are in line with previous 
literature. In this review, testosterone therapy produced many cases of benign PSA increase. 
In literature, studies have consistently found small increases in PSA in some patients 
commencing therapy, but either no cases of BCR or a recurrence rate lower than that 
expected without therapy (47). The promising secondary results of this review also suggest 
that testosterone therapy was effective in improving symptoms of deficiency in most patients 
and that it caused very few non-recurrence adverse effects. This is in agreement with 
published evidence for testosterone therapy in men with testosterone deficiency: a meta-
analysis by Zheng et al established that therapy improves symptoms, increases testosterone 
levels and does not cause serious adverse reactions (8, 48).  
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Limitations of the review 
 
The BCR rate in this review was unexpectedly low compared to BCR rates in high-risk 
patients in literature. Rather than pointing towards a protective effect of testosterone therapy, 
this is likely to be the result of limitations of the review. Several potential sources of bias may 
have led to the underestimation of risks of treatment. Notably, the average follow-up time 
from the initiation of testosterone therapy was 30.5 months and varied greatly, with some 
patients being followed for as little as one month. This is not long enough to determine the 
safety of long-term testosterone therapy, given that high-risk patients have been found to 
experience a peak in BCR at four to six years (49). Additionally, although Figure 2B does not 
reveal any publication bias, five abstracts were excluded from the review because they lacked 
the detailed patient characteristics necessary for risk grouping. Furthermore, patient selection 
was neither randomised nor consecutive and was vulnerable to selection bias: it is likely that 
patients perceived to be lower risk, even within the high-risk category, were chosen for 
treatment with this controversial therapy. There may also have been reporting bias whereby 
authors were more likely to retrospectively include patients who were successfully treated, or 
attrition bias if treatment was discontinued quickly in patients showing signs of adverse 
effects or recurrence.  
 
Other limitations included the small number of patients and studies, which demonstrates the 
limited research into testosterone therapy for this high-risk group, and the quality of evidence 
of those studies. 11 of 13 included studies were observational, non-randomised, non-blinded 
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and non-controlled case series or studies. Pastuszak et al (10) did compare their patients to a 
group not receiving testosterone therapy but the reference patients were not testosterone 
deficient and not an ideal control group. Due to the lack of a control group and the low event 
rate, an unconventional single-arm meta-analysis was performed. 10 retrospective studies that 
often provided incomplete information were included in the review. The prospective studies, 
in turn, may have been vulnerable to information bias in the recording of data. (3, 30, 34) 10 
studies were single centre and 11 were North American, limiting their generalisability. All of 
the studies had an OCEBM Level of Evidence of just four out of five, demonstrating their 
very low quality of evidence. IHE Quality Assessment, similarly, revealed an average level of 
evidence of just 8.6 out of 18. The average score of 10 for the four studies that identified 
cases of BCR compared to an average of 7.7 for those that did not, suggesting that adverse 
events might have been missed by less robust methodology. The IHE scores may have been 
biased against the three included studies for which only conference abstracts were available, 
as they had less available details of patients and methodology – nevertheless, the very low 
level of evidence overall leaves us in need of larger scale prospective trials to obtain more 
reliable data. Furthermore, six studies were not designed to look specifically at high-risk 
patients and the included studies were statistically underpowered to individually assess the 
effect of testosterone therapy on high-risk patients.  
 
There was significant variation in methods and definitions between studies. In addition to 
variation in follow-up period, testosterone therapy varied by route of administration: the 
various methods used were oral administration, subcutaneous pellets, intramuscular 
injections, and transdermal gels and patches. There were also differences in definition of 
testosterone deficiency and indications for prescribing testosterone therapy, reflecting 
inconsistency in the literature and adding to the clinical heterogeneity of the review. All 
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patients experienced symptoms of testosterone deficiency prior to starting therapy, with the 
exception of three men treated by Kühn et al with low serum testosterone but no symptoms 
(28).  Conversely, Pastuszak et al treated men with symptoms of deficiency even if their 
testosterone levels were in normal range (10, 28). Only six studies included specific threshold 
serum testosterone levels below which therapy was initiated, ranging from serum testosterone 
of 300 to 350 ng/dl and free serum testosterone of 10.0 to 11.7 ng/dl. Testosterone therapy 
was prescribed after different time periods from the end of prostate cancer treatment: in 
theory, symptom improvements and PSA changes attributed to early testosterone therapy 
could have been due to the prolonged effects of prostate cancer treatment. Additionally, there 
was inconsistency in the definition of high-risk prostate cancer. The high-risk patients in nine 
of the included studies matched the d’Amico criteria, but two studies used the National 
Comprehensive Cancer Network guidelines (29, 31) and two studies defined high risk as 
having a Gleason score greater than 8, positive surgical margins or positive lymph nodes after 
radical prostatectomy (10, 41). The patients also received a range of treatments for prostate 
cancer. Notably, patients in six of the included studies were treated with ADT, which can 
lead to extended reductions in testosterone level, especially after use for over 36 months (50), 
and may have contributed to the patients’ testosterone deficiency and reaction to testosterone 
therapy.  
 
A final limitation was the use of BCR as the primary outcome measure. The BCR rates varied 
widely from zero to 50%, largely due to the small numbers of high-risk patients in individual 
studies. There was inconsistency in the definition of BCR, which is an already unreliable 
measure of recurrence. In some cases recurrence may not cause BCR, whilst in others BCR 
can be a ‘false alarm,’ especially given that small transient or sustained PSA rises can occur 
with initiation of testosterone therapy, in line with the prostate saturation model. (26) Such 
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rises in PSA were documented in nine of the included studies, and small PSA rises have even 
been found in placebo groups in studies of testosterone therapy in hypogonadal men. (25) 
Indeed, the presence of BCR did not indicate the patients’ outcome at last follow-up in the 
included studies. Of the nine cases of BCR, five were in radiotherapy patients and four were 
in prostatectomy patients, with large variation in their outcomes. Two were found to be 
disease-free on further histological or radiological investigation, whereas five began salvage 
therapy, including one who developed pelvic metastases. Two had unclear outcomes: one 
discontinued therapy but their PSA remained elevated, and the other was not investigated 
further for evidence of disease but their PSA continued to rise, reaching 40 ng/ml at last 
follow-up (10). This suggests that the rate of histological or radiological recurrence in these 
studies was even lower than the rate of BCR, and further demonstrates the unreliability of 
BCR as a measure of recurrence.  
 
Recommendations for clinical practice 
 
The results of this review suggest that there might not be any increased risk of BCR with 
testosterone therapy in testosterone-deficient survivors of curatively treated high-risk prostate 
cancer. The secondary outcomes point towards testosterone therapy improving symptoms of 
testosterone deficiency and quality of life in this population of patients. Nevertheless, the 
available evidence is of very low quality and should be applied to clinical practice with 
caution. Decisions to start and continue therapy must be made with detailed discussion of 
potential benefits and risks with patients, including discussing the current lack of robust 
evidence and discussing possible adverse effects and cardiovascular risk. It should be offered 
to patients who suffer from symptoms of deficiency that severely impact their quality of life 
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and cannot be attributed to comorbidities. Starting treatment with short-acting formulations is 
recommended, as it allows for rapid withdrawal in case of adverse effects or suspected 
recurrence (5). We echo recommendations (3, 34) to wait for PSA to reach a nadir, ideally 
below 1 ng/ml, between prostate cancer treatment and initiation of testosterone therapy to 
reduce confusion between benign post-treatment PSA increases and BCR. Crucially, patients 
should be fully screened for active disease before initiating therapy, and monitored closely 
during treatment.  
 
Recommendations for future research 
 
We would recommend that future research into treatment of survivors of prostate cancer with 
testosterone therapy group patients by risk for all study outcomes. We recommend that trials 
be prospective and include a control group of prostate cancer survivors with symptoms of 
testosterone deficiency but not receiving testosterone therapy. Randomised controlled trials 
would significantly improve the quality of the evidence. Larger trials with longer follow-up 
are also necessary, given the very low event rate in the included studies. Long-term follow-up 
over at least five years would be beneficial to establish the long-term safety of testosterone 
therapy, and applying a minimum length of follow-up is crucial to interpreting BCR rates. 
There should be clarity and consistency in the definitions of testosterone deficiency, 
administration of testosterone therapy and BCR. The outcomes of suspected cases of BCR 
should be recorded to determine both the number of cases of BCR and the number of 
confirmed recurrences of disease. The management of patients’ prostate cancer, including the 
duration of ADT, should be recorded.  
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Conclusions 
 
This systematic review and meta-analysis found that there was no increased rate of BCR in 
survivors of curatively treated high-risk prostate cancer receiving testosterone therapy for 
testosterone deficiency compared to the rate of BCR in high-risk prostate cancer survivors in 
literature. This suggests that testosterone therapy may not present an increased recurrence 
risk in this group, and may be considered for patients with symptoms of testosterone 
deficiency. However, the body of evidence is small and of very low quality, and this therapy 
remains investigational in this group.  
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Figure legends 
 
 
Figure 1. PRISMA flow chart demonstrating the literature search process. 
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Figure 2. Meta-analysis results. A) Forest plot demonstrating the rates of BCR in 
survivors of curatively treated high-risk prostate cancer in the included studies. The 
net risk of biochemical recurrence was 0.00 (confidence interval 0.00-0.005). The I2-
value suggests that 0.00% of the variation in the included studies may have been 
due to statistical heterogeneity. The p-value of 0.72 indicates that the statistical 
heterogeneity in the included studies may not be significant. B) Funnel plot of 
included studies does not reveal any publication bias.  
 
Table 1. Characteristics of the included studies and their BCR rates in high-risk patients. BCR = 
Biochemical recurrence, RP = radical prostatectomy, ADT = androgen deprivation therapy, 
EBRT = External beam radiation therapy, HIFU = high intensity focused ultrasound. 
Study  Study 
size 
(Number 
of high-
risk 
patients) 
  
IHE 
Score 
(0- 
18) 
OCEBM 
Level of 
Eviden-
ce (1-5) 
Mean / 
median 
months 
follow-
up* 
period  
(range)  
Prostate 
cancer 
treatment 
received 
(number 
of 
patients) 
BCR 
cases 
(High-
risk 
BCR 
cases) 
% 
BCR in 
high-
risk 
group 
Ory et al. 
Oct 2016  
82 (30) 10 4 41 (22-
57) 
RP +/- 
ADT (22) 
0 0 % 
Radio-
therapy 
+/- ADT 
(50) 
3 (2)  9.52% 
Other +/- 
ADT (10) 
0 0 % 
Ravi et al. 
Apr 2016  
1 (1) 6 4 - EBRT (1) 0 0% 
Pastuszak 
et al.  
Nov 2015  
98 (11) 11 4 40.8 
(1.5 - 
147) 
 
 
Radio-
therapy 
+/- ADT 
(96) 
6 (2)  18.2% 
Kühn et al. 
Sept 2015 
32 (4) 7 4 39.8 
(12-108) 
RP (26), 
EBRT 
(1), 
0  0% 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
   
 
 27 
brachy-
therapy 
(3), HIFU 
(2) 
Bryant et 
al.  
Dec 2014  
23 (2) 8 4 38  Proton 
therapy 
+/- ADT 
0 0% 
Balbontin 
et al.  
Jul 2014  
20 (1) 12 4 31 (12-
48) 
Brachy-
therapy 
+/- EBRT 
(20) 
0 0% 
Pastuszak 
et al.  
Aug 2013  
103 (26) 9 4 27.5 
(6.2-
189.3) 
RP +/- 
ADT, 
radiation 
therapy, 
gene 
therapy, 
chemo-
therapy 
(103)   
4 (4) 15.4% 
Pastuszak 
et al.  
Jan 2013  
13 (2) 10 4 29.7 
(2.3– 
67.3) 
Brachy-
therapy 
(3), 
ERBT 
(10), +/- 
ADT (4) 
1 (1) 50% 
Sathyamo-
orthy et al. 
Apr 2010  
133 (21) 7 4 12  RP 0 0% 
Khera et 
al. Apr  
2009  
57 (4) 9 4 13 (1-
99) 
RP 0 0% 
Morales et 
al.  
Jan 2009  
5 (3) 8 4 14.5 (6-
27) 
EBRT 0 0% 
Sarosdy. 
Feb 2007  
31 (3) 7 4 60 (18 - 
108) 
Brachy-
therapy 
+/- EBRT, 
ADT (31) 
0 0% 
Agarwal 
and 
Oefelein. 
Feb 2005  
10 (1) 8 4 19 RP (10) 0 0% 
* Follow-up period from the initiation of testosterone therapy  
 
 
